Shield Therapeutics PLC Appointment of Non-Executive Director (8012V)
26 July 2018 - 4:02PM
UK Regulatory
TIDMSTX
RNS Number : 8012V
Shield Therapeutics PLC
26 July 2018
Shield Therapeutics plc
("Shield" or the "Company")
Appointment of Non-Executive Director
London, UK, 26 July 2018: Shield Therapeutics plc (LSE:STX), a
commercial stage, pharmaceutical company delivering innovative
specialty pharmaceuticals to address patients' unmet medical needs,
with an initial focus on addressing iron deficiency, is pleased to
announce the appointment of Hans-Peter Hasler as a Non-Executive
Director of the Company with immediate effect.
Mr Hasler is the founder and CEO of Vicarius Pharma and an
Advisor to SBTech Global Advisory. His prior experience includes
roles as COO, Elan Corporation, and several senior positions at
Biogen, Inc., including Chief Operations Officer. Previously, Mr.
Hasler was at Wyeth Pharmaceuticals as Senior Vice President, Chief
Marketing Officer and Managing Director of Wyeth Group Germany,
Wyeth-Lederle Switzerland, Austria and CEE. Mr Hasler is Chairman
of HBM Healthcare Investments AG in Switzerland, Chairman of MIAC
Medical Imaging Analysis Center of the University Hospital of
Basel, and a Director of the Board of Minerva Neuroscience Inc.,
Boston.
Carl Sterritt, CEO of Shield Therapeutics, said: "On behalf of
the Board I'd like to welcome Hans-Peter to Shield and trust his
broad experience of commercial operations and negotiations in
pharmaceutical transactions will be a great asset to the Company in
the coming months and beyond."
Regulatory Disclosures
The following disclosures are required regarding Hans-Peter's
appointment pursuant to Schedule Two paragraph (g) of the AIM Rules
for Companies:
Full name and age: Hans-Peter Hasler, aged 62
Hans-Peter holds or has held the following directorships in the
five years preceding his appointment at the Company:
Current Directorships Former Directorships
HBM Healthcare Investment AG Acino Holding AG
MIAC AG AOP Orphan Pharmaceuticals
Minerva Neuroscience Inc. Celltrion Inc.
Vicarius Pharma AG Dr Reddy's Labs
Ferring Holding S.A.
Pantheon N.V.
Rigi Healthcare AG
No further disclosure is required under AIM Rule 17 and
paragraph (g) to Schedule Two of the AIM Rules with respect to
Hans-Peter Hasler.
- Ends -
For further information please contact:
Shield Therapeutics plc +44 (0)207 186 8500
Carl Sterritt, Chief Executive Officer
Nominated Advisor and Joint Broker +44 (0)203 100 2222
Liberum Capital Limited
Christopher Britton/Steve Pearce
Joint Broker +44 (0)207 418 8900
Peel Hunt LLP
James Steel/ Dr Christopher Golden
Financial PR Advisor +44 (0)203 709 5700
Consilium Strategic Communications
Mary-Jane Elliott/Matthew Neal
About Shield Therapeutics plc
Shield is a commercial stage, pharmaceutical company delivering
innovative specialty pharmaceuticals to address patients' unmet
medical needs. Our clear purpose is to help our patients become
people again, by enabling them to enjoy the things that make the
difference in their everyday lives. The Group has a marketed
product, Feraccru(R), for the treatment of IDA in adult patients
with IBD which has exclusive IP rights until the mid-2030's. For
more information please visit www.shieldtherapeutics.com.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
BOADBGDRRGDBGIU
(END) Dow Jones Newswires
July 26, 2018 02:02 ET (06:02 GMT)
Shield Therapeutics (LSE:STX)
Historical Stock Chart
From Apr 2024 to May 2024
Shield Therapeutics (LSE:STX)
Historical Stock Chart
From May 2023 to May 2024